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Abstract
1. Purpose
This research focused on the adoption of Six Sigma within FDA-regulated pharmaceutical companies
to design and propose an effective CAPA system for reducing the cost of noncompliance and
supporting organizational performance.
2. Design/Methodology/Approach
This study utilized the DMAIC methodology, in a case study, to improve the CAPA process within a
medical device company regulated by the FDA. Critical requirements for compliance CAPA system
was defined from FDA sources and a DMAIC model was be applied to improve and maintain CAPA
performance.
3. Findings
Using the DMAIC approach, the authors identifyed process variation within the current CAPA
process. A stepwise-based CAPA model is proposed for company adoption.
4. Research Limitations/Implications
This research was limited to the aspects of CAPA regulation as one important regulatory
requirement, within the FDA regulatory environment. This study was limited in its description: that
being the Six Sigma DMAIC process was utlilzed to define the case study’s current CAPA issues and
propose a new CAPA system. Further research is needed to confirm these results and application of
Six Sigma within the regulatory sector.
5. Practical Implications
This research serves as an approach for the Six Sigma practitioner to familiarize, and potentially
adopt in similar, highly regulated environments, within the life sciences sector.
6. Value
This paper expands knowledge of quality system regulation through this novel application of Six
Sigma in designing an effective CAPA approach. This could allow companies to gain a greater
understanding of conducting effective systems compliance more efficiently.
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Introduction
Within the pharmaceutical sector, implementing an effective corrective action and preventive
action (CAPA) system is critical, not only because it is a regulatory requirement, but, because it is
a helpful tool for continuous improvement. It is a mandatory by the regulatory bodies i.e. the U.S.
Food and Drug Administration (FDA), that drug and medical devices-based industries adopt a
mature CAPA system for three main reasons:
-

Regulatory requirements: A prerequisite for ISO-certified and FDA-regulated companies.
Customer satisfaction: Capability to deal with any customer-related issue and correct any
quality problem is crucial for better customer relationship and for sustained customer
satisfaction.
- Better business performance: Problems and quality issues would financially impact
companies.
Six Sigma methodology is a tactical methodology that has been used in most of industrial
sectors for about 25 years to improve process performance. It was established by Motorola in the
1980s and started to be implemented by others such as General Electric.. Six Sigma is a flexible
data-driven approach used to save money, improve capabilities and performance, achieve better
customer relationships, and therefore, achieve near-perfection performance at all business levels.
This approach relies on facts and statistical analytical thinking to detect and eliminate nondesirable variations and defects in the processes. Sigma principles consist of a business strategy
and methodology that has the ability to improves business performance and operational efficiency,
improves product quality, reduces production costs, and improves customer satisfaction, especially
considering the growth of global markets.
Six Sigma DMAIC consists of five stages; Define, Measure, Analyze, Improve, and Control
Stage one is ‘Define’ where opportunities are defined, while stage two ‘Measure’ is to measure
the current process performance. ‘Analyze’ is the third stage where possible opportunities are
analyzed, stage four which is ‘Improve”, where methods to improve performance are proposed,
and finally ‘Control’ where ways to control performance are completed.. Six
Within a healthcare organization, Six Sigma could be used as a catalyst for compliance. Six
Sigma consists of several components that ensure the effective running of organization and
implementation of a regulatory compliance program. Six Sigma could allow a more consistent
compliance program, which has a high value in the compliance field.
In this study, a Six Sigma DMAIC module was applied within a medical device company to
improve their CAPA process, with the goal to achieve the required compliance with the FDA
regulation. Within this medical device company, this research was conducted on the company’s
CAPA process within the quality assurance department
Six Sigma and CAPA
Adopting Six Sigma for the pharmaceutical industry need to pay close diligence attention
when identifying customers because the customer definition varies, compared to other industries.
For pharmaceutical industries, although the patients are the end customers, there are third-party
customers. The real customers are the doctors prescribing drugs, the pharmacist willing to stock
certain medicine and the governments who oversee socialized healthcare. These governments have
enormous buying power and wield this power to negotiate pricing of pharmaceutical products.
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Therefore, pharmaceutical organization should consider these regulatory agencies as one of
their customers who help generate additional revenue and profits. Six Sigma can be used to
improve the CAPA process by considering the FDA as the customer for CAPA and define their
critical requirements then using the model Define, Measure, Analyze, Improve, and Control
(DMAIC) to improve the CAPA process performance and sustain improved performance.
Adopting the concept and benefits of Six Sigma to create an effective CAPA system (Good CAPA
practice) supportsa more efficient and productive business.
There are drug and medical devices-based companies that have implemented Six Sigma, and
are successfully using it to accomplish their corporate strategies such as Baxter, Eli Lilly, Johnson
& Johnson, and Novartis (Stückrath 2006), only a few of these firms are listed among the member
companies of the International Society for Six Sigma Professionals (ISSSP) (Liu 2005). Although
the pharmaceutical/medical device manufacturering sector is a highly controlled sector in order to
make sure that all the regulatory requirements are followed and implemented by companies to
produce and deliver high-quality products and therefore, protect patients' safety, there are still
many critical processes that not meeting the needs of today’s marketplace (Cortada et al, 2004).
Finding and following a strategic methodology that helps companies maintain their best
compliance status and achieve a continuous business improvement is important. Six Sigma itself
is not just a statistical tool, it is a strategic methodology that can be used to produce quantifiable
and significant changes within the company by using data, which in turn, is used to operate
compliance system and processes to the maximize compliance performance, with the ulitimate
goal to finally improve customers’ satisfaction (FDA) and reduce compliance costs (Roan &
Jernelid, 2009). Therefore, the ultimate goal for CAPA process improvement is to bring the process
to maximum compliance as well as reduce the cost of non-compliance. Tarantino (2008) suggested
that having a Six Sigma program in place could help the organization in many ways. One benefit
that relates to this study is by reducing variation, which is also what a compliance program aims
achieve consistently Table 1 summarizes CAPA aspects that professionals address.
Table 1. CAPA in the literature
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Moreover, In the author opinion adopting a Six Sigma program helps many pharmaceutical
companies to eliminate non-added values and allows production operations to change effectively.
Therefore, instead of depending on the final quality control and testing, Six Sigma allows
organizations to detect and expect problems and errors therefore enhance the process efficacy
which ultimately enhances both quality and compliance. This case study applies Six Sigma
DMAIC principles, with the goal of improving CAPA. The definition of CAPA requirments, in
this case, are through FDA’s Warning Letter as criterion for an effective CAPA system.
Case Study
The company under study is a medical device company regulated by the FDA. The
company originally started as a University-industry partnership with a primary focus on
developing medical device products. This primary focus rapidly expanded to include other
supportive service areas of pre-clinical, clinical, and non-clinical research, medical and scientific
writing, as well as regulatory policies and approaches. The case study company CAPA related data
are collected. The company CAPA procedure is looked up under their quality assurance
department to collect data and gain an insight overview on the current performance of their CAPA
process. When bearing in mind process improvement both efficiency and effectiveness should be
considered. However, this study will focus only on improving the effectiveness of the CAPA
process. Due to time limitation, the last stage of the DMAIC approach (control stages) will be
delivered to the case study company as suggestions and recommendations.
Define Phase
In the Define phase, after evaluation of the FDA CAPA-related warning letters, the voice of
the customer (VOC) was defined, This VOC was translated into critical customer requirements
(CCRs) which in turn, were used to identify the critical to quality (CTQ’s) attributes. A project
charter in Figure 1 outlines the project as well as identiying the main stakeholders.The project
charter created a roadmap for team members to understand the business value of the project and
understand how the project was aligned with the organizational strategy.

Figure 1, Project Charter
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Critical customer requirements (Table 2) were identified from the norms and criteria for good
CAPA practices, and voice of the customer (VOC) analysis. For highly regulated industries, such
as medical devices and pharmaceutical companies, the customer (FDA) is the final authority that
determines the final value of any regulatory process ( https://www.fda.gov/about-fda/fdahistory/milestones-us-food-and-drug-law ). FDA's decision to approve a company’s compliance
status is based on a system of critical FDA regulation and requirements.
Table 2. Critical customer requirements

Table 3 Process SIPOC
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Table 3 gives a high-level understanding of the CAPA process through a Supplier, Input,
Process, Output, Customer (SIPOC) analysis. The SIPOC describes how the process uses relevant
inputs, provided by the CAPA process suppliers, to bring the deliverable outputs to the CAPA
process customers, primarily the FDA.
Measure Phase
The second stage of DMAIC was intended to measure the current performance of the CAPA
process within the case study company. Thisestablished the process baseline and measured the gap
between the current performance and the target performance, defined previously from the VOC in
the Define stage. A qualitative analysis of attributes between current and ideal CAPA process was
conducted by the team. Table 4 summarizes the identified gaps in the CAPA system.
Table 4. Current performance/ GAP within the system

Analyze Phase
The Analyze stage was conduted to identify causes for the process gaps identified above. To
improve the CAPA process, the Analysis phase was concerned with the evaluation of the ways the
work was performed currently in order to identify the reasons why these gaps exist. Figure 2
illustrates the application of 5 ‘whys’ tool used to identify root cause. The deliverable root
cause,which was the major output from the analyze stagewas found that no single guideline or
CAPA program approach could guide the company to fulfill all the FDA regulatory requirements
or bring the best practice to the company’s CAPA system.
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Why?

• CAPA system is not in compliance with the FDA regulation

• There are gaps between what the FDA required and the current
performance
Why?
Why?
Why?

• The FDA requirements are not fully implemented
• Difficulty in defining and interpreting the CAPA requirement per the
regulations

• No single source that clearly defines how to design, develop and implement
a CAPA system that meets all the regulatory requirements
Why?
Figure 2. The 5 Whys root cause analysis
Improve Phase
Use of a process ‘turtle’ analysis technique, the team devised a new procedure for meeting
regulatory requirements. The CAPA process turtle (figure 3) reveals the need to design a new
process able to cover all the regulatory criteria. This proposed model is a stepwise approach as
each step acts as an input to the next step. It consists of 11 steps that cover all the CAPA system
regulatory requirements to meet best CAPA practices.

Figure 3. CAPA process turtle analysis
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Control Phase
the last stage of the Six Sigma DMAIC application is the control stage, where alternative design
ideas were recommended to the organization, to improve, and ultimately, maintain compliance
performance.. The project team created multiple ideas for maintenance. These ideas included:
•

Creating a CAPA checklist to ensure that all CAPA regulatory requirements are covered
during CAPA detection and execution.
• Using tracking and monitor tool to record and monitor all CAPA activities.
• Categorization of the CAPA finding to facilitate the tracking process.
Develop metrics to measure CAPA process performance and capability.Figure 4 shows a
CAPA process improvement cycle, as wheel of continuous improvement, and how the use of the
Six Sigma DMAIC principles could allow for the development of a general CAPA model,
implementing Six Sigma aspects, to ultimately, control and maintain improved compliance
through effective performance.

Figure 4. CAPA system performance improvement within Six Sigma principles
Conclusions and Recommendations
A medical device company, through a case study, applied the Six Sigma DMAIC approach to
analyze current CAPA problems, through the lens of FDA compliance, to present changes to the
current CAPA process for adoption. A step-wise approach was presented, along with more general,
and multi-pronged approach to redesigning an effective CAPA system. This research could be
considered descriptively and needs further testing. More empirical research is needed to
statistically test the significance of the new proposed model. Additionally, the generalizability of
this new model should be examined by applying it to various case studies companies.However,
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this research provides a novel application of the Six Sigma DMAIC methodology in improving a
CAPA process to meet FDA regulations. This could give pharmaceutical/medical device
manufacturers guidance to redesign a more effective CAPA system.
A stepwise-based CAPA model, based upon a process ‘turtle’ model is proposed to support an
organization’s compliance with FDA requirements and also for an effective CAPA
structure. Other potential adoption principles include the adoption of well-designed checklist(s)
to make sure that t CAPA activites are efficiently accomplished. This proposed CAPA model could
helps companies in their continuous improvement journeyof compliance and performance.
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